Review of Effect of Tirzepatide on Glycemic Control and Weight Loss
by Rachael L. Koch, 2023 PharmD Candidate, Rachel K. Schneider, 2023 PharmD Candidate, Megan A. Mills, 2023 PharmD Candidate, Michael W. Nagy, PharmD, BCACP
Tirzepatide (Mounjaro) is a new to market glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist. It has shown to substantially decrease hemoglobin A1c as demonstrated in the SURPASS trials. Additionally, the SURMOUNT-1 trial showed the impact tirzepatide can have on weight reduction independent of diabetes. Tirzepatide has just been implemented into the American Diabetes Association guideline recommendations for type 2 diabetes management with emphasis on weight reduction as of 2023. The current clinical data and upcoming trials have promising evidence to make a significant impact for patients with type 2 diabetes and/or obesity. In this article, we review the clinical trial data for tirzepatide and the applications for pharmacy practice.
Keywords: Tirzepatide, Glycated Hemoglobin, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose
Download PDF
2023 May/June Table of Contents
Tirzepatide (Mounjaro) is a new to market glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist. It has shown to substantially decrease hemoglobin A1c as demonstrated in the SURPASS trials. Additionally, the SURMOUNT-1 trial showed the impact tirzepatide can have on weight reduction independent of diabetes. Tirzepatide has just been implemented into the American Diabetes Association guideline recommendations for type 2 diabetes management with emphasis on weight reduction as of 2023. The current clinical data and upcoming trials have promising evidence to make a significant impact for patients with type 2 diabetes and/or obesity. In this article, we review the clinical trial data for tirzepatide and the applications for pharmacy practice.
Keywords: Tirzepatide, Glycated Hemoglobin, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose
Download PDF
2023 May/June Table of Contents